Sustained Control of a High-Risk ISUP 2 Prostate Adenocarcinoma Associated with an Experimental Apoptosis-Inducing Intervention: A Case Report with 33-Month Follow-Up
This case report documents a 33-month follow-up of a patient with high-risk ISUP 2 prostate adenocarcinoma who, after declining conventional treatment and initiating an experimental apoptosis-inducing intervention, achieved sustained biochemical control, metabolic regression on PET imaging, and significant functional improvements, suggesting a therapeutic effect inconsistent with the disease's natural history.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your body as a bustling city where every cell is a citizen. Normally, when a citizen gets damaged or starts acting weird, the city has a built-in "self-destruct" button called apoptosis. It's like a gentle, programmed exit that keeps the neighborhood tidy and safe. But sometimes, in diseases like prostate cancer, these rogue cells ignore the self-destruct button. They keep multiplying, building illegal structures, and crowding out the good citizens. This is especially tricky when the cancer is "high-risk," meaning it's aggressive and likely to spread if not stopped. Doctors usually have a standard toolkit to fight this—surgery, radiation, or hormone therapy—but what happens if someone tries a completely different, experimental approach? This story isn't about a magic cure-all; it's about a single, unusual case where a man with a stubborn form of cancer tried a new, experimental method to force those rogue cells to hit their self-destruct buttons, and the results were surprisingly different from what doctors usually expect.
This case report tells the story of a 66-year-old man who was diagnosed with a high-risk type of prostate cancer (specifically called ISUP 2) in 2023. His "cancer alarm," a blood marker called PSA, was already ringing loudly at 32 ng/mL and climbed to 52.23 ng/mL by April 2024. In the world of prostate cancer, a PSA this high usually means the tumor is growing fast and will likely spread to bones or lymph nodes within a few years. Without standard treatment, doctors predict his PSA would have skyrocketed to between 200 and 300 ng/mL by 2026.
Instead of surgery or radiation, this man chose to decline conventional treatment and started an experimental intervention on his own. He used a special agent designed to trigger apoptosis—essentially forcing the cancer cells to commit suicide. He stuck with this plan for 33 months, from September 2023 to June 2026.
Here is where the story gets fascinating. While the cancer usually acts like a runaway train, this man's body seemed to hit the brakes.
- The Blood Test: His PSA, which should have been soaring, stayed stuck in a "plateau" at or below 52.23 ng/mL for the entire 33 months. It never went higher.
- The Scans: In 2024, a special camera scan (a ¹⁸F-fluorocholine PET-CT) showed two bright, hot spots in his prostate with a high activity score of 7.40. Two years later, in 2026, a different camera scan (using ¹⁸F-FDG) showed only one spot, and it was much dimmer, with a lower activity score of 3.08. Crucially, the cancer had not spread to other parts of his body.
- How He Felt: The most surprising part was how his daily life improved. When he started, he had to wake up constantly at night to pee (nocturia) and could only release tiny amounts of urine (70–80 mL). By 2026, he was sleeping 7–8 hours straight without waking up, and his urine volume had doubled to a healthy 180–200 mL. Even his sexual health, which was weak in 2024, returned to normal by mid-2026.
The authors of the paper explain that the prostate gland actually looked larger on the 2026 scan. Normally, a growing gland means the cancer is getting worse. However, the authors suggest this might be a "cleanup crew" effect. When a massive number of cancer cells die at once (apoptosis), the body sends in immune cells to clean up the debris, causing temporary swelling and inflammation. They argue this enlargement was likely a sign of healing, not growth.
The paper concludes that this combination of a stable PSA, less active cancer on scans, and a return to normal bodily functions is extremely unlikely to happen by chance or without treatment. The authors suggest that this experimental "self-destruct" intervention might have worked, but they are careful to say this is just one story. They emphasize that more research is needed to prove exactly how the agent works and to see if it helps others. For now, this case stands as a curious, hopeful puzzle that doesn't fit the usual rules of how this cancer behaves.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.